ArticleCell death & disease2025
Targeting TIMM23 to overcome osteosarcoma chemoresistance.
Article in Cell death & disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Targeting CD3L1-NRP2 disarms myeloid-driven tumor immune evasion.EMBO molecular medicine · 2026Article
- Single-cell mitophagy patterns dictate intercellular crosstalk in the tumor microenvironment to promote osteosarcoma progression.Translational cancer research · 2026Article
- Deciphering the malignant synergy: metabolic reprogramming, epigenetic circuitry, and niche remodeling in osteosarcoma-macrophage crosstalk.Frontiers in immunology · 2026Review
- Remodeling the tumor immune microenvironment: mechanisms of crosstalk between regulated cell death macrophages.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteosarcoma (OS) is a malignant tumor whose chemoresistance severely compromises therapeutic efficacy. This study aims to investigate the molecular mechanism by which TIMM23 mediates M2 polarization of macrophages through mitophagy and regulates TIMM23-PARGP1 fusion gene expression and chemoresistance in OS. Single-cell transcriptomic analysis revealed a strong interaction between macrophages and tumor cells. By integrating bulk RNA sequencing data and weighted gene co-expression network analysis (WGCNA) co-expression network analysis, we identified TIMM23 as a key gene associated with macrophage polarization. Using STAR-Fusion, we further detected the TIMM23-PARGP1 fusion gene, which was validated via fluorescence in situ hybridization (FISH). CRISPR/Cas9 was employed to generate TIMM23-knockout macrophages, and a lentiviral system was used to create TIMM23-overexpressing macrophages. Flow cytometry demonstrated that TIMM23 promotes M2 polarization, while confocal and transmission electron microscopy confirmed its role in regulating mitophagy in M2 macrophages. These findings indicate that TIMM23 promotes M2 polarization through mitophagy modulation. Next, a co-culture model of macrophages and OS cells was established. MTT, Cell Counting Kit-8 (CCK-8), EdU, Transwell, and TUNEL assays were performed to evaluate tumor cell behavior and chemosensitivity. The results showed that TIMM23-induced M2 polarization upregulated TIMM23-PARGP1 expression in OS cells, thereby enhancing their proliferation, migration, and invasion while inhibiting apoptosis and reducing the effectiveness of chemotherapeutic agents. In vivo experiments further confirmed the role of TIMM23 in promoting M2 polarization and fusion gene expression, leading to increased chemoresistance and tumor growth. In conclusion, TIMM23 enhances OS chemoresistance and tumor progression by promoting M2 macrophage polarization via mitophagy and upregulating TIMM23-PARGP1 fusion gene expression. Graphical Abstract. Molecular mechanism diagram illustrating the involvement of TIMM23 in mitophagy-mediated M2 polarization of macrophages and the impact of TIMM23-PARGP1 fusion gene on chemoresistance in OS (Created with BioRender.com).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.